A5017835821- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Nutrition and Health in Aging
- Advanced Breast Cancer Therapies
- Cancer Risks and Factors
- Breast Lesions and Carcinomas
- Immune cells in cancer
- Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Radiomics and Machine Learning in Medical Imaging
- Pancreatic and Hepatic Oncology Research
- Radiopharmaceutical Chemistry and Applications
- Chronic Lymphocytic Leukemia Research
- PI3K/AKT/mTOR signaling in cancer
- Brain Metastases and Treatment
- Colorectal Cancer Treatments and Studies
- Monoclonal and Polyclonal Antibodies Research
- Ferroptosis and cancer prognosis
- BRCA gene mutations in cancer
- Histone Deacetylase Inhibitors Research
- Cancer survivorship and care
Agostino Gemelli University Polyclinic
2018-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2019-2025
Università Cattolica del Sacro Cuore
2019-2024
University of Verona
2014-2023
Azienda Ospedaliera Universitaria Integrata Verona
2012-2023
Federico II University Hospital
2018
Ospedale Vito Fazzi
2017-2018
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
2018
Azienda Ospedaliero Universitaria Ospedali Riuniti
2018
IRCCS Ospedale San Raffaele
2018
Hormone receptor-positive/HER2-negative breast cancer (BC) is the most common subtype of BC and typically occurs as an early, operable disease. In patients receiving neoadjuvant chemotherapy (NACT), pathological complete response (pCR) rare multiple efforts have been made to predict disease recurrence. We developed a framework pCR using clinicopathological characteristics widely available at diagnosis. The machine learning (ML) models were trained (n = 463), evaluated in internal validation...
Tumor-associated macrophages (TAM) are regulators of extracellular matrix (ECM) remodeling and metastatic progression, the main cause cancer-associated death. We found that disabled homolog 2 mitogen-responsive phosphoprotein (DAB2) is highly expressed in tumor-infiltrating TAMs its genetic ablation significantly impairs lung metastasis formation. DAB2-expressing TAMs, mainly localized along tumor-invasive front, participate integrin recycling, ECM remodeling, directional migration a...
In metastatic colorectal cancer (mCRC), BRAFV600E mutation has been variously associated to specific clinico-pathological features. Two large retrospective series of mCRC patients from two Italian Institutions were used as training-set (TS) and validation-set (VS) for developing a nomogram predictive status. The model was internally externally validated. the TS, data 596 gathered (RAS wild-type (wt) 281 (47.1%); mutated 54 (9.1%)); RAS mutations mutually exclusive. RAS-wt population,...
Abstract Background. The role of tumor-infiltrating lymphocytes (TILs) in breast cancer (BC) is still an issue for clinical research. Toward this end, a sensitivity analysis neoadjuvant and adjuvant randomized trials was performed according to disease subtypes. Methods. Pathological complete responses (pCRs) after treatment the presence or absence lymphocyte-predominant BC (LPBC) were extracted cumulated as odds ratios (ORs) by adopting random-effects model subtype. Overall survival hazard...
We aimed to assess the efficacy of neoadjuvant chemotherapy (NACT) in a cohort 213 triple‐negative breast cancer (TNBC) patients treated real‐world practice at eight Italian centers. computed descriptive statistics for all variable interest. Factors testing significant univariate analysis were included multivariate models. Survival data compared by Kaplan–Meier curves and log‐rank test. The median follow‐up was 45 months. observed 60 (28.2%) pathological complete response (pCR). sequential...
Aim Pathological predictive factors are the most important markers when selecting early breast cancer adjuvant therapy. In randomized clinical trials variability in pathology report after central review is noteworthy. We evaluated discordance rate (DR) and inter-rater agreement between local histopathological implication on treatment decision. Methods A retrospective analysis was conducted a series of consecutive tumors diagnosed by pathologists subsequently reviewed at Pathology Division...
Tumor dissemination to the central nervous system (CNS) is almost a rule in treatment journey of advanced HER2+ breast cancer (BC). Recent results demonstrated high intracranial efficacy with Trastuzumab Deruxtecan (T-DXd). However, real-world evidence lacking literature. We conducted multicenter, observational, retrospective analysis on 39 cases collected at 12 Italian Oncological Units. Patients brain metastases (BMs) from HER2 + BC treated T-DXd various lines were enrolled. Primary...
We carried out a retrospective observational study of 264 HER2-positive advanced breast cancer (ABC) patients to explore the efficacy first-line treatment with pertuzumab/trastuzumab/taxane in real-world setting. Survival data were analyzed by Kaplan Meier curves and log rank test.Median follow-up, length pertuzumab, trastuzumab maintenance 21, 4 15 months, respectively. The response rate was 77.3%, clinical benefit 93.6%. Median progression-free survival (mPFS) 21 median overall (mOS) not...